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Abstract
The bacterial CRISPR/Cas9 system for genome editing has greatly expanded the toolbox for
mammalian genetics, enabling the rapid generation of isogenic cell lines and mice with modified
alleles. Here, we describe a pooled, loss-of-function genetic screening approach suitable for both
positive and negative selection that uses a genome-scale lentiviral single guide RNA (sgRNA)
library. sgRNA expression cassettes were stably integrated into the genome, which enabled a
complex mutant pool to be tracked by massively parallel sequencing. We used a library containing
73,000 sgRNAs to generate knockout collections and performed screens in two human cell lines.
A screen for resistance to the nucleotide analog 6-thioguanine identified all expected members of
the DNA mismatch repair pathway, while another for the DNA topoisomerase II (TOP2A) poison
etoposide identified TOP2A, as expected, and also cyclin-dependent kinase 6, CDK6. A negative
selection screen for essential genes identified numerous gene sets corresponding to fundamental
processes. Finally, we show that sgRNA efficiency is associated with specific sequence motifs,
enabling the prediction of more effective sgRNAs. Collectively, these results establish Cas9/
sgRNA screens as a powerful tool for systematic genetic analysis in mammalian cells.
A critical need in biology is the ability to efficiently identify the set of genes underlying a
cellular process. In microorganisms, powerful methods allow systematic loss-of-function
genetic screening (1, 2). In mammalian cells, however, current screening methods fall short
– primarily because of the difficulty of inactivating both copies of a gene in a diploid
mammalian cell. Insertional mutagenesis screens in cell lines that are near-haploid or carry
Blm mutations, that cause frequent somatic crossing-over, have proven powerful but are not
applicable to most cell lines and suffer from integration biases of the insertion vectors (3, 4).
The primary solution has been to target mRNAs with RNA interference (RNAi) (5–9).
However, this approach is also imperfect as it only partially suppresses target gene levels
and can have off-target effects on other mRNAs – resulting in false negative and false
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positive results (10–12). Thus, there remains an unmet need for an efficient, large-scale, loss
of function screening method in mammalian cells
Recently, the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
pathway, which functions as an adaptive immune system in bacteria (13), has been co-opted
to engineer mammalian genomes in an efficient manner (14–16). In this two-component
system, a single guide RNA (sgRNA) directs the Cas9 nuclease to cause double-stranded
cleavage of matching target DNA sequences (17). In contrast to previous genome-editing
techniques, such as zinc-finger nucleases and TALENs, the target specificity of CRISPR/
Cas9 is dictated by a 20-base pair sequence at the 5′-end of the sgRNA, allowing for much
greater ease of construction of knockout reagents. Mutant cells lines and mice bearing
multiple modified alleles can be generated with this technology (18, 19).
We set out to explore the feasibility of using the CRISPR/Cas9 system to perform large-
scale, loss-of-function screens in mammalian cells. The idea was to use a pool of sgRNA-
expressing lentivirus to generate a library of knockout cells that could be screened under
both positive and negative selection. Each sgRNA would serve as a distinct DNA barcode
that can be used to count the number of cells carrying it using high-throughput sequencing
(Fig. 1A). Pooled screening requires that single-copy sgRNA integrants are sufficient to
induce efficient cleavage of both copies of a targeted locus. This contrasts with the high
expression of sgRNAs achieved by transfection that is typically used to engineer a specific
genomic change using the CRISPR/Cas9 system.
We first tested the concept in the near-haploid, human KBM7 CML cell line, by creating a
clonal derivative expressing the Cas9 nuclease (with a FLAG-tag at its N-terminus) under a
doxycycline-inducible promoter (Fig. 1B). Transduction of these cells at low multiplicity of
infection (MOI) with a lentivirus expressing a sgRNA targeting the endogenous AAVS1
locus revealed substantial cleavage at the AAVS1 locus 48 hours after infection (Fig. 1C).
Moreover, because the sgRNA was stably expressed, genomic cleavage continued to
increase over the course of the experiment. Deep sequencing of the locus revealed that repair
of Cas9-induced double-strand breaks resulted in small deletions (<20 bp) in the target
sequence, with tiny insertions or substitutions (<3 bp) occurring at a lower frequency (Fig.
1D). The vast majority of the lesions, occurring in a protein-coding region, would be
predicted to give rise to a nonfunctional protein product, indicating that CRISPR/Cas9 is an
efficient means of generating loss-of-function alleles.
We also analyzed off-target activity of CRISPR/Cas9. Although the specificity of CRISPR/
Cas9 has been extensively characterized in transfection-based settings (20–22), we wanted
to examine its off-target behavior in our system, where Cas9 and a single guide RNA
targeting AAVS1 (sgAAVS1) were stably expressed for two weeks. We compared the level
of cleavage observed at the target locus (97%) to levels at 13 potential off-target cleavage
sites in the genome (defined as sites differing by up to 3 bp from sgAAVS1). Minimal
cleavage (<2.5%) was observed at all sites with one exception, which was the only site that
had perfect complementarity in the ‘seed’ region (terminal 8 bp). On average, sgRNAs have
~2.2 such sites in the genome, almost always (as in this case) occurring in non-coding DNA
and thus less likely to affect gene function (Note S1).
To test the ability to simultaneously screen tens of thousands of sgRNAs, we designed a
sgRNA library with 73,151 members, consisting of multiple sgRNAs targeting 7,114 genes
and 100 non-targeting controls (Methods, Fig. 1E, Table S1). sgRNAs were designed
against constitutive coding exons near the beginning of each gene and filtered for potential
off-target effects based on sequence similarity to the rest of the human genome (Fig. 1, F
and G). The library included 10 sgRNAs for each of 7033 genes and all possible sgRNAs for
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each of the 84 genes encoding ribosomal proteins (Fig. 1H). To assess the effective
representation of our microarray synthesized library, we sequenced sgRNA barcodes from
KBM7 cells 24 hours after infection with the entire lentiviral pool and were able to detect
the overwhelming majority (>99%) of our sgRNAs, with high uniformity across constructs
(only 6-fold increase in abundance between the 10th and 90th percentiles) (Fig. S2A).
As an initial test of our approach, we screened the library for genes that function in DNA
mismatch repair (MMR). In the presence of the nucleotide analog 6-thioguanine (6-TG),
MMR-proficient cells are unable to repair 6-TG-induced lesions and arrest at the G2-M cell-
cycle checkpoint, while MMR-defective cells do not recognize the lesions and continue to
divide (23). We infected Cas9-KBM7 cells with the entire sgRNA library, cultured the cells
in a concentration of 6-TG that is lethal to wild-type KBM7 cells, and sequenced the sgRNA
barcodes in the final population. sgRNAs targeting the genes encoding the four components
of the MMR pathway (MSH2, MSH6, MLH1 and PMS2) (24) were dramatically enriched in
the 6-TG-treated cells. At least four independent sgRNAs for each gene showed very strong
enrichment and barcodes corresponding to these genes made up >30% of all barcodes (Fig.
2, A and B). Strikingly, each of the twenty most abundant sgRNAs targeted one of these
four genes. The fact that few of the other 73,000 sgRNAs scored highly in this assay
suggests a low frequency of off-target effects.
We next addressed the challenge of loss of function screening in diploid cells, which require
bi-allelic inactivation of a target gene. We therefore generated an inducible Cas9 derivative
of the HL60 pseudo-diploid human leukemic cell line. In both HL60 and KBM7 cells, we
screened for genes whose loss conferred resistance to etoposide, a chemotherapeutic agent
that poisons DNA topoisomerase IIA (TOP2A). To identify hit genes, we calculated the
difference in abundance between the treated and untreated populations for each sgRNA,
calculated a score for each gene by using a Kolmogorov-Smirnov test to compare the
sgRNAs targeting the gene against the non-targeting control sgRNAs, and corrected for
multiple hypothesis testing (Fig. 2, C to E, Table S2). Identical genes were detected in both
screens, with significance levels exceeding all other genes by more than 100-fold. As
expected, loss of TOP2A itself conferred strong protection to etoposide (25). The screen also
revealed a role for CDK6, a G1 cyclin-dependent kinase, in mediating etoposide-induced
cytotoxicity. Notably, every one of the 20 sgRNAs in the library targeting TOP2A or CDK6
was strongly enriched (>90th percentile) in both screens, indicating that the effective
coverage of our libraries is very high. We generated isogenic HL60 cell lines with individual
sgRNAs against TOP2A and CDK6 and, consistent with the screen results, these lines were
much more resistant to etoposide than parental or sgAAVS1-modified HL60 cells (Fig. 2, F
and G). Thus, our Cas9/sgRNA system enables large-scale positive selection loss-of-
function screens.
To identify genes required for cellular proliferation we screened for genes whose loss
conferred a selective disadvantage on cells. Such a screen requires accurate identification of
sgRNAs that are depleted from the final cell population. Importantly, a sgRNA will show
depletion only if cleavage of the target gene occurs in the majority of cells carrying the
construct.
As an initial test, we screened KBM7 cells with a small library containing sgRNAs targeting
the BCR and ABL1 genes (Table S3). The survival of KBM7 cells depends on the fusion
protein produced by the BCR-ABL translocation (26). As expected, depletion was seen only
for sgRNAs targeting the exons of BCR and ABL1 that encode the fusion protein, but not for
those targeting the other exons of BCR and ABL1 (Fig. 3A).
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We then infected Cas9-HL60, Cas9-KBM7, and WT KBM7 cells with the entire 73,000-
member sgRNA library and used deep sequencing of the sgRNA barcodes to monitor the
change in abundance of each sgRNA between the initial seeding and a final population
obtained after twelve cell doublings (Fig. S2, A and B).
We began by analyzing ribosomal proteins genes, for which the library contained all
possible sgRNAs. We observed strong Cas9-dependent depletion of sgRNAs targeting genes
encoding ribosomal proteins, with good concordance between the sets of ribosomal protein
genes essential for cell proliferation in the HL60 and KBM7 screens (the median sgRNA
fold-change in abundance was used as a measure of gene essentiality) (Fig. 3, B and C).
Interestingly, a few ribosomal protein genes were not found to be essential. These were two
genes encoded on chromosome Y (RPS4Y2, which is testes-specific (27), and RPS4Y1,
which is expressed at low levels compared to its homolog RPS4X on chromosome X (28)),
and ‘ribosome-like’ proteins, which may be required only in select tissues (27) and generally
are lowly expressed in KBM7 cells (Fig. S3A).
We then turned our attention to other genes within our dataset, for which ten sgRNAs were
designed. As for the ribosomal genes, the essentiality scores of these genes were also
strongly correlated between the two cells lines (Fig. S3B, Table S4). For the twenty highest
scoring genes, we found independent evidence for essentiality, based primarily on data from
large-scale functional studies in model organisms (Table S5).
To evaluate the results at a global level, we tested 4722 gene sets to see if they showed
strong signatures of essentiality, using Gene Set Enrichment Analysis (29). Gene sets related
to fundamental biological processes – including DNA replication, gene transcription, and
protein degradation – showed strong depletion, consistent with their essentiality (Fig. 3D,
Table S6).
Finally, we sought to understand the features underlying sgRNA efficacy. Although the vast
majority of sgRNAs against ribosomal protein genes showed depletion, detailed comparison
of sgRNAs targeting the same gene revealed substantial variation in the precise amounts of
depletion. These differences are unlikely to be caused by local accessibility to the Cas9/
sgRNA complex inasmuch as comparable variability was observed even among sgRNAs
targeting neighboring target sites of a given gene (Fig. S4A). Given that our library includes
all possible sgRNAs against each of the 84 ribosomal genes, the data allowed us to search
for factors that might explain the differential efficacy of sgRNAs. Because the majority of
ribosomal proteins genes are essential, we reasoned that the level of depletion of a given
ribosomal protein-targeting sgRNA could serve as a proxy for its cleavage efficiency.
Applying this approach, we found several trends related to sgRNA efficacy: (1) Single guide
sequences with very high or low GC content were less effective against their targets. (2)
sgRNAs targeting the last coding exon were less effective than those targeting earlier exons,
consistent with the notion that disruption of the terminal exon would be expected to have
less impact on gene function. (3) sgRNAs targeting the transcribed strand were less effective
than those targeting the non-transcribed strand (Fig. 3E). Although these trends were
statistically significant, they explained only a small proportion of differences in sgRNA
efficacy (Table S7).
We hypothesized that differences in sgRNA efficacy might also result from sequence
features governing interactions with Cas9. To test this, we developed a method to profile the
sgRNAs directly bound to Cas9 in a highly parallel manner (Methods). By comparing the
abundance of sgRNAs bound to Cas9 relative to the abundance of their corresponding
genomic integrants, we found that the nucleotide composition near the 3′-end of the spacer
sequence was the most important determinant of Cas9 loading (Fig. 3F). Specifically, Cas9
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preferentially bound sgRNAs containing purines in the last 4 nucleotides of the spacer
sequence whereas pyrimidines were disfavored. A similar pattern emerged when we
examined depletion of ribosomal protein-targeting sgRNAs (r=0.81), suggesting that, in
significant part, the cleavage efficiency of a sgRNA was determined by its affinity for Cas9
(Table S7).
We then sought to build an algorithm to discriminate between strong and weak sgRNAs
(Fig. 3G). We trained a support-vector-machine classifier based on the target sequences and
depletion scores of ribosomal protein-targeting single guide RNAs. As an independent test,
we used the classifier to predict the efficacy of sgRNAs targeting the 400 top scoring (i.e.
essential) non-ribosomal genes. The top two-thirds of our predictions exhibited 3-fold higher
efficacy than the remaining fraction, confirming the accuracy of the algorithm.
Using this algorithm, we designed a whole-genome sgRNA library consisting of sequences
predicted to have higher efficacy (Table S8). As with the sgRNA pool used in our screens,
this new collection was also filtered for potential off-target matches. This reference set of
sgRNAs may be useful both for targeting single genes as well as large-scale sgRNA
screening.
Taken together, these results demonstrate the utility of CRISPR/Cas9 for conducting large-
scale genetic screens in mammalian cells. Based on our initial experiments, this system
appears to offer several powerful features that together provide significant advantages over
current functional screening methods.
First, CRISPR/Cas9 inactivates genes at the DNA level, making it possible to study
phenotypes that require a complete loss of gene function to be elicited. In addition, the
system should also enable functional interrogation of non-transcribed elements, which are
inaccessible by RNAi.
Second, a large proportion of sgRNAs successfully generate mutations at their target sites.
While this parameter is difficult to directly assess in pooled screens, we can obtain an
estimate by examining the ‘hit rate’ at known genes. Applying a z-score analysis of our
positive selection screens, we find that over 75% (46/60) of sgRNAs score at a significance
threshold that perfectly separates true and false positives on a gene level (Fig. S5, A to D).
Together these results show that the effective coverage of our library is very high and that
the rate of false negatives should be low even in a large-scale screen.
Third, off-target effects do not appear to seriously hamper our screens, based on several
lines of evidence. Direct sequencing of potential off-target loci detected minimal cleavage at
secondary sites, which typically reside in non-coding regions and do not impact gene
function. Moreover, in the 6-TG screens, the twenty most abundant sgRNAs all targeted one
of the four members of the MMR pathway. In total, they represented over 30% of the final
pool, a fraction greater the next 400 sgRNAs combined. In the etoposide screen, the two top
genes scored far above background levels (p-values 100-fold smaller than the next best
gene), enabling clear discrimination between true and false positive hits. Lastly, new
versions of the CRISPR/Cas9 system have recently been developed that substantially
decrease off-target activity (30, 31).
Although we limited our investigation to proliferation-based phenotypes, our approach can
be applied to a much wider range of biological phenomena. With appropriate sgRNA
libraries, the method should enable genetic analyses of mammalian cells to be conducted
with a degree of rigor and completeness currently possible only in the study of
microorganisms.
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Fig. 1. A pooled approach for genetic screening in mammalian cells using a lentiviral CRISPR/
Cas9 system
(A) Outline of sgRNA library construction and genetic screening strategy (B) Immunoblot
analysis of wild-type KBM7 cells and KBM7 cells transduced with a doxycycline inducible
FLAG-Cas9 construct upon doxycycline induction. S6K1 was used as a loading control. (C)
Sufficiency of single copy sgRNAs to induce genomic cleavage. Cas9-expressing KBM7
cells were transduced with AAVS1-targeting sgRNA lentivirus at low MOI. The
SURVEYOR mutation detection assay was performed on cells at the indicated days post-
infection (dpi). Briefly, mutations resulting from cleavage of the AAVS1 locus were
detected through PCR amplification of a 500-bp amplicon flanking the target sequence, re-
annealing of the PCR product and selective digestion of mismatched heteroduplex
fragments. (D) Characterization of mutations induced by CRISPR/Cas9 as analyzed by high-
throughput sequencing. (E) sgRNA library design pipeline. (F) Example of sgRNAs
designed for PSMA4. sgRNAs targeting constitutive exonic coding sequences nearest to the
start codon were chosen for construction. (G) Composition of genome-scale sgRNA library.
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Fig. 2. Resistance screens using CRISPR/Cas9
(A) Raw abundance (%) of sgRNA barcodes after 12 days of selection with 6-thioguanine
(6-TG). (B) Mismatch repair (MMR) deficiency confers resistance to 6-TG. Diagram depicts
cellular DNA repair processes. Only sgRNAs targeting components of the DNA MMR
pathway were enriched. Diagram modified and adapted from (32). (C) Primary etoposide
screening data. The count for a sgRNA is defined as the number of reads that perfectly
match the sgRNA target sequence. (D) sgRNAs from both screens were ranked by their
differential abundance between the treated versus untreated populations. For clarity,
sgRNAs with no change in abundance are omitted. (E) Gene hit identification by comparing
differential abundances of all sgRNAs targeting a gene to differential abundances of non-
targeting sgRNAs in a one-sided Kolmogorov-Smirnov test. p-values are corrected for
multiple hypothesis testing. (F) Immunoblot analysis of WT and sgRNA-modified HL60
cells 1 week after infection. S6K1 was used as a loading control. (G) Viability, as measured
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by cellular ATP concentration, of WT and sgRNA-modified HL60 cells at indicated
etoposide concentrations. Error bars denote standard deviation (n=3).
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Fig. 3. Negative selection screens using CRISPR/Cas9 reveal rules governing sgRNA efficacy
(A) Selective depletion of sgRNAs targeting exons of BCR and ABL1 present in the fusion
protein. Individual sgRNAs are plotted according to their target sequence position along
each gene and the height of each bar indicates the level of depletion observed. Boxes
indicate individual exons. (B) Cas9-dependent depletion of sgRNAs targeting ribosomal
proteins. Cumulative distribution function plots of log2 fold changes in sgRNA abundance
before and after twelve cell doublings in Cas9-KBM7, Cas9-HL60 and WT-KBM7 cells.
(C) Requirement of similar sets of ribosomal protein genes for proliferation in the HL60 and
KBM7 cells. Gene scores are defined as the median log2 fold change of all sgRNAs
targeting a gene. (D) Depleted sgRNAs target genes involved in fundamental biological
processes. Gene Set Enrichment Analysis was performed on genes ranked by their combined
depletion scores from screens in HL60 and KBM7 cells. Vertical lines underneath the x-axis
denote members of the gene set analyzed. (E) Features influencing sgRNA efficacy.
Depletion (log2 fold change) of sgRNAs targeting ribosomal protein genes was used as an
indicator of sgRNA efficacy. Correlation between log2 fold changes and spacer %GC
content (left), exon position targeted (middle) and strand targeted (right) are depicted.
(*p<0.05) (F) sgRNA target sequence preferences for Cas9 loading and cleavage efficiency.
Position-specific nucleotide preferences for Cas9 loading are determined by counting
sgRNAs bound to Cas9 normalized to the number of corresponding genomic integrations.
Heatmaps depict sequence-dependent variation in Cas9 loading (top) and ribosomal protein
gene-targeting sgRNA depletion (bottom). The color scale represents the median value (of
Cas9 affinity or log2 fold-change) for all sgRNAs with the specified nucleotide at the
specified position. (G) sgRNA efficacy prediction. Ribosomal protein gene-targeting
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sgRNAs were designated as ‘weak’ or ‘strong’ based their log2 fold change and used to train
a support-vector-machine (SVM) classifier. As an independent test, the SVM was used to
predict the efficacy of sgRNAs targeting 400 essential non-ribosomal genes. (*p<0.05)
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